Impact of elective resection on plasma TIMP-1 levels in patients with colon cancer

Colorectal Disease

Volumn 8, Issue 3, 2006, Pages 168-172

  Hammer, J H ^a   Basse, L ^a   Svendsen, M N ^a   Werther, K ^a   Brunner N ^b   Christensen, I J ^a   Nielson, Hans Jørgen ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Colon cancer; Fast track recovery; Laparoscopic surgery; Open surgery; Prognosis; TIMP 1

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COLON CANCER; COLON DISEASE; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTIVE SURGERY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN INCISION; SURGICAL APPROACH; SURGICAL INJURY;

AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LAPAROSCOPY; LINEAR MODELS; MALE; MIDDLE AGED; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 33644910722     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2005.00831.x     Document Type: Article

References (26)

1. Tomiak A, Vincent M, Kocha W et al. Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: Prohibitory toxicity? Am J Clin Oncol 2000; 23: 94-8.
2. Figuerode A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: A systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22: 3395-407.
3. Brünner N, Nielsen HJ, Hamers MJ et al. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999; 107: 160-7.
4. Diamandis E, Fritsche HA, Lilja H, Chan DW, Schwartz MH. (2002) Tumor Markes. Physiology, pathobiology, technology, and clinical applications. pp. 1 - 541. AACC press, New York.
5. Stamenkovic I. Extracellular matrix remodelling: The role of matrix metalloproteinases. J Pathol 2003; 200: 448-64.
6. Holten-Andersen MN, Murphy G, Nielsen HJ et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80: 495-503.
7. Holten-Andersen MN, Stephens RW, Nielsen HJ et al. High preoperative plasma tissue inhibitor of matalloproteinases-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292-9.
8. Holten-Andersen MN, Christensen IJ, Nilbert M et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases-1 and rectal cancer patient survival: A validation study. Eur J Cancer 2004; 40: 64-72.
9. Holten-Andersen M, Nielsen HJ, Sørensen S et al. Predicting minimal residual disease during follow-up of colorectal cancer patients by measurement of tissue inhibitor of metalloproteinases-1 in plasma. Int J Biol Markers 2002; 17: 35-36.
10. Nielsen HJ. The effect of histamine-2 receptor antagonists on posttraumatic immune competence. Dan Med Bull 1995; 42: 162-74.
11. Kehlet H, Nielsen HJ. Impact of laparoscopic surgery on stress responses, immunofunction, and risk of infectious complications. New Horiz 1998; 6: 80-8.
12. Basse L, Hjort Jacobsen D, Bardram L et al. Functional recovery after open versus laparoscopic colonic resection: A randomized, blinded study. Ann Surg 2005; 241: 416-23.
13. Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet 2003; 362: 1921-8.
14. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrica 1986; 73: 13-22.
15. Holten-Andersen MN, Christensen IJ, Nielsen HJ et al. Total levels of Tissue Inhibitor of MetalloProteinases-1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156-64.
16. Holten-Andersen MN, Brünner N, Christensen IJ, Jensen V, Nielsen HJ. Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. Scand J Clin Laboratory Invest 2002; 62: 223-30.
17. Pugin J, Widmer MC, Kossodo S, Liang CM, Preas HL, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458-64.
18. Takafuji S, Ishida A, Miyakuni Y, Nakagawa T. Matrix metalloproteinase-9 release from human leukocytes. J Invest Allergol Clin Immunol 2003; 13: 50-5.
19. Galley HF, Macaulay GD, Webster NR. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and tumour necrosis factor α release during cardiopulmonary bypass. Anaesthesia 2002; 57: 659-62.
20. Baker EA, Leaper DJ. Profiles of matrix metalloproteinases and their tissue inhibitors in intraperitoneal drainage fluid: Relationship to wound healing. Wound Repair Regen 2003; 11: 268-74.
21. Guedez L, Courtemanch L, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase (TIMP) -1 induces differentiation and an anti-apoptotic phenotype in germinal center B cells. Blood 1998; 92: 1342-9.
22. Chromek M, Tullus K, Lundahl J, Brauner A. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immunity 2004; 72: 82-8.
23. Holten-Andersen MN, Christensen IJ, Nielsen HJ et al. (2002) TIMP-1 in colorectal cancer. In: Tumour Markers, Physiology, Pathobiology, Technology, and Clinical Applications. (eds. Diamantis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK) pp. 440 - 3. AACC Press, Washington.
24. Svendsen MN, Werther K, Kristjansen PE, Nielsen HJ. VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation, and blood transfusion. Scand J Gastroenterol 2002; 37: 373-9.
25. Hanke B, Wein A, Martus P et al. Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer 2003; 88: 1248-50.
26. Holten-Andersen MN, Christensen IJ, Nielsen HJ et al. Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay. Clin Chem 2002; 48: 1305-13.